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The action of 5-fluorouracil on human HT29 colon
cancer cells grown in SCID mice: mitosis, apoptosis and
cell differentiation
R Sharma, E Adam and U Schumacher
Human Morphology, University of Southampton, Southampton S016 7PX, UK
Summary This study investigates the effects of the anti-metabolite 5-fluorouracil (5-FU) on the human colon cancer line HT29 (107 cells per
dose) grown subcutaneously in severe combined immunodeficient (SCID) mice. The efficacy of 5-FU was quantitatively evaluated by
comparing the tumour weight, mitotic and apoptotic tumour cell indices and the expression of the Ki-67 nuclear antigen in drug-treated
animals and control animals. The tumour cell carbohydrates were assessed using a lectin panel. A significant reduction in the tumour weight
was found 4 days after initial 5-FU treatment. 5-FU treatment reduced the percentages of mitoses but increased the apoptotic index in the
tumour cells. In addition, 5-FU induced an increase in the signet ring cell population and an increased binding for lectins specific for N-
acetylgalactosamine and galactose. However, the vast majority of signet ring cells were negative for Ki-67. The results of this study indicate
that continuous treatment with 5-FU for 4 days targets metabolic processes relevant for both cell division and apoptosis. The relative increase
in the signet ring population can be explained by the fact that the more proliferation-active stem cell population of the tumour is the primary
target of the therapy. The lectin-binding patterns reflect these changes and are therefore differentiation linked.
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Colorectal adenocarcinoma is one of the six most common
cancers in the Western world and represents a serious clinical
problem (Silveberg and Lubera, 1989). The clinical problem
arises from the fact that tumour cells circulate and metastasize to
the liver and to other distant sites, these metastases being the main
cause of death in colon cancer (Bengmark and Hafstrom, 1969;
Ho et al, 1994). Most of the previous meta-analytic studies of
randomized clinical trials of tumour response rate and overall
survival could not find definitive proofofthe benefits ofsystemic
chemotherapy (Buyse et al, 1.988). In contrast, recent multi-
centre clinical trials have re-emphasized the role of adjuvant
chemotherapy in colorectal cancer and show a more positive
outlook than previous studies (Cunningham and Findlay, 1991).
In particular, the role of5-fluorouracil (5-FU) as part ofa combi-
nation therapy in the treatment ofcolorectal carcinoma has under-
gone a revival and recent clinical studies indicate its benefits as a
chemotherapeutic agent in the treatment of colorectal carcinoma
(Laffer, 1995; Marsoni, 1995).
The anti-tumour activity of 5-FU is dependent on the ability of
the drug to bind and inactivate the enzyme thymidylate synthase
(TS). TS converts deoxyuridine monophosphate to deoxythymidine
monophosphate, thereby blocking the de novo synthesis of
thymine (Pratt and Taylor, 1990). A lack ofthe latter compound in
tumour cells results in the inability of the cells to synthesize
DNA and they accumulate at the beginning of the S-phase
(Camplejohn et al, 1977).
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Although the effects of anti-metabolites on the cell cycle of
tumour cells are well established, various additional effects of
anti-metabolites on cell differentiation (Momoi et al, 1986) and
glycosylation (Peters et al, 1990; De Graff et al, 1993) have also
been investigated. 5-FU, in particular, induces an increase in the
incorporation of radioactive glucosamine, galactose, fucose and
mannose into the cellular glyconjugates of leukaemic mouse
L1210 cells (Peters et al, 1990). However, no comprehensive
studies on effects of 5-FU on cell proliferation and changes in
glycosylation of tumour cells have been performed in an in vivo
model. We chose a human/SCID mouse animal model to test the
influence of 5-FU on cell proliferation, apoptosis and glycosyla-
tion as this model system has been proven to be of clinical rele-
vance (Schumacher et al, 1994a,b).
MATERIALS AND METHODS
Animals
Four groups of ten pathogen-free BALB/c C57BL/Kalgh-I
scid/scid (SCID) mice, aged 12-16 weeks, were used in this study.
Animals obtained from our breeding colony were maintained
under sterile conditions and wereprovided with sterilized food and
water ad libitum.
All experimental manipulations were undertaken aseptically
inside laminar flow facilities.
Transplantation of HT-29 human carcinoma cell line
The human colon carcinoma cell line HT29 was obtained from the
American Type Culture Collection through the European Tissue
Culture Collection (Porton Down, Salisbury, UK) and maintained
under standard conditions as indicated in the data sheet supplied
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with the cells. The cells were harvested by trypsinization, the
viability was tested (> 95%) and 5 x 107 viable cells were resus-
pended in 1 ml ofMcCoy's 5A medium.
Each recipient SCID mouse was injected subcutaneously with
200 ,ul of the cell suspension (1 x 107) into the back between the
scapulae.
Treatment of animals
Nineteen days (day 19) after HT29 cell transplantation, a substan-
tial growth of subcutaneous tumour was seen in the scapular
region of the mice. Animals were randomly divided into control
and experimental (treatment) groups. Two groups of ten mice
received intraperitoneal injections of 5-FU three times daily for
4 days (days 20, 21, 22, 23 after tumour implantation; morning,
lunchtime, evening) at a dose of 50 mg kg-' body weight
dissolved in physiological saline as previously established by
Imaizumi et al (1993). Another two groups of mice, used as
controls, were injected with physiological saline three times daily
on days 20, 21, 22 and 23. The mice were then left untreated. One
control group and one treatment group were killed by cervical
dislocation the following day (day 24); the remaining two groups
were killed on day 26.
Evaluation of animals, tumours and histological
methods
The body weight ofthe mice was recorded before the initiation of
treatment and was monitored during the course of the study. The
tumour was excised from each mouse, weighed, fixed in 10%
buffered formalin and embedded in paraffin wax. Tissue blocks
were sectioned at a thickness of 6 jim and processed for routine
histological examination using haematoxylin and eosin staining.
Sections were also subjected to the periodic acid-Schiff (PAS)
reaction for characterizing unsubstituted a-glycol-rich neutral
mucins.
The assessment of cell proliferation in the tumour population
was made by high-temperature immunohistochemical unmasking
technique using the mouse monoclonal antibody NCL-Ki67-MM1
(Novocastra Laboratories, Newcastle upon Tyne, UK). Sections
were dewaxed and placed into a pressure cooker containing
preboiled 0.01 M sodium citrate buffer (pH 6.0). When the pres-
sure indicator valve had risen, sections were incubated for a
further minute. After washing in distilled water and Tris-buffered
saline (TBS) buffer, sections were placed in 1.5% hydrogen
peroxide in methanol for 10 min, washed in distilled water and
TBS buffer and incubated in normal horse serum for 20 min.
Incubation with the primary anti-serum (1:100) in TBS was
carried out for 30 min at room temperature in a Shandon Sequenza
immunostaining centre. This was followed by abriefwash in TBS,
and incubation for 30 min in the secondary anti-serum (biotinyl-
ated horse anti-mouse immunoglobulin G, 1:200). After a further
wash in TBS sections were treated with avidin-biotin-peroxidase
(ABC) complex from peroxidase standard PK-4000 (Vector
Laboratories, Peterborough, UK) for 30 min, washed again in
TBS, and then incubated in diaminobenzidine tetrahydrochloride
(DAB) in Tris-HCl buffer pH 7.3 with 0.001% hydrogen peroxide
for 5-10 min. The controls included use of TBS in place of the
primary antiserum. Sections were stained with the PAS procedure,
mounted in DPX and examined by light microscopy.
Quantitative and statistical methods
The percentage ofcells showing mitotic figures, apoptotic bodies,
Ki-67 positive enterocytes and signet ring cells in ten different
areas ofthe tumour, delineatedby an eyepiece graticule (170 jim2),
was determined by counting a minimum of 500 cells from each
animal. The areas of measurement were standardized: one corner
of the eyepiece graticule was positioned at the tumour-host inter-
face with an objective lens ofmagnification 4 and counting ofthe
mitotic and apoptotic figures was carried out at the same site using
an objective lens of magnification 40. Only cells that were in
easily recognizable meta- and anaphases were counted as mitotic,
whereas those cells with a dissolved nuclear membrane and dense
basophilic inclusion bodies were counted as apoptotic (see Figure
2 for an example ofboth).
The results were expressed as means per group ± s.e.m. and
statistical differences between the two groups were analysed for
significance by the Mann-Whitney non-parametric test using the
Prism version 2 (GraphPad Software, SanDiego, CA, USA).
Differences between groups with at least P < 0.05 were considered
to be significant.
Lectin histochemistry
Paraffin sections were cut at 6 jm, deparaffinized in xylene,
hydrated through a series ofgraded alcohols andbrought to 0.05 M
TBS at pH 7.7 containing 0.1% calcium chloride. Sections were
then trypsinized with 0.1% trypsin (Sigma) in 0.05 M TBS for 30
min at 25°C. After a wash in TBS, the endogenous peroxidase
activity was blocked with 0.3% hydrogen peroxide in methanol.
Sections were washed again in TBS and incubated for 30 min at
room temperature in a Shandon Sequenza immunostaining centre
with the biotinylated lectins (Sigma, EY Laboratories, Vector
Laboratories) at a concentration of 10 jig ml-' in TBS. The lectins
used in this study, their sources, abbreviations and sugar specifici-
ties are listed in Table 1. After a further wash in TBS, sections
were treated with ABC complex (Peroxidase standard PK-4000,
Vector Laboratories) for 30 min, washed again in TBS, and then
incubated in DAB in Tris-HCl buffer pH 7.3 with 0.3% hydrogen
peroxide for 5-10 min. The control experiments were carried out
by omission of the lectin and by incubation of the sections
with the lectins and their appropriate inhibitory sugars (0.3 M
final concentration) except for SNA, in which neuraminidase
predigestion was used. Sections were lightly counterstained with
Harris's haematoxylin, mounted in DPX and examined by light
microscopy. Photographs were taken on Kodak TMAX 400 black
and white film.
RESULTS
Weight loss in tumour-bearing animals
The effects of 5-FU treatment on the body weight of the SCID
mice as compared with controls before, during and after the treat-
ment revealed no significant differences in body weight between
the two groups throughout the experiment.
Tumour weight
Figure 1 shows the tumour weight of the human colonic tumour
xenografts in SCID mice at days 24 and 26 afterthe intraperitoneal
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Table 1 Lectins used, their abbreviations and sugar specificities
Lectin (common name) Abbreviation Nominal carbohydrate specificitya Sugar inhibitor
Triticum vulgare (wheat germ) WGA GIcNAc(l1,4GlcNAc)1_3 GIcNAc
>,BGlcNac > NeuAc
Phytolacca americana (pokeweed) PWM GlcNAc(j1,4GlcNAc)1 3= (Gall1,4GlcNac)2-5 GIcNAc
Glycine max(Soy bean) SBA a,pGalNAc > a,pGal GaINAc
Sophorajaponica (pagoda tree) SJA a,jGalNAc > a,,Gal GaINAc
Vicia villosa (hairy vetch) VVA GalNAcal,3GalNAco axGalNAc GaINAc
Wisteria floribunda WFA GalNAcal,6Gal> GalNAcll ,6Gal > GalNAcal,3Gal GaINAc
Sambucus nigra SNA Neu5Aca2,6Gal > GaINAc Neuraminidase
Ulex europaeus (gorse seed) UEA-1 a-Fuc Fuc
Arachis hypogaea (peanut) PNA Terminal GaIl1,3GaINAc Gal
aAffinity for simple sugars or monosaccharides in solution. Fuc, fucose; Gal, galactose; Glc, glucose; GIcNAc, N-acetylglucosamine; GaINAc,
N-acetylgalactosamine; Man, mannose; NeuAc, neuraminic acid (sialic acid).
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Figure 1 Mean (± s.e.m.) tumour weight of 5-FU-injected SCID mice and
controls at days 24 and 26. *Significantly different from controls at P< 0.005.
M, Control; *, 5-Fu
5-FU administration compared with the saline-injected controls.
At day 26, treatment with 5-FU significantly reduced (P < 0.005)
the tumour weight in comparison with the controls.
Histological studies
The histology of xenotransplants of the colonic adenocarcinoma
showed signet ring type cells, enterocyte-like differentiated
tumour cells and stromal fibroblasts. Apoptotic cells and cells
showing mitotic figures were identified (Figure 2) among the
tumour cells, some of which had differentiated into signet ring
cells, which are characterized by intracellular mucin vacuoles and
their tangentially located flattened nucleus. The central parts ofthe
tumours were often necrotic. The transplanted tumours were
encapsulated by a thin connective tissue capsule, which was occa-
sionally interrupted by tumour cells migrating out.
The mean percentages of mitoses in all tumour cells at day 24
and day 26 were significantly lower (P < 0.0001) in animals
treated with 5-FU, but the mean percentages of apoptotic cells
were increased (P < 0.0001) compared with the controls (Figure
3). However, in 5-FU-treated SCID mice, the mean percentages of
Ki-67 positive enterocyte-like differentiated tumour cells were
significantly more at day 24 and less at day 26 (P < 0.0001 and
Figure 2 HT29 tumour cells showing mitosis (single arrow) and apoptosis
(double arrow) in a SCID mouse injected with 5-FU at day 26. S, signet ring
cell. Haematoxylin and eosin staining. Bar = 25 gm
P < 0.0001 respectively) compared with controls (Figure 3). The
expression of Ki-67 nuclear antigen was seen in the enterocyte-
like differentiated tumour cells and was very rarely present in
signet ring cells (Figure 4).
PAS reaction and lectin histochemistry
In both saline- and 5-FU-treated SCID mice, the signet ring cell
tumour cells at the transplanted site showed PAS-positive secretion
droplets. However, the tumours from 5-FU-treated animals when
compared with those injected with saline showedconsiderably more
signet ring cells containing intracellular mucin (Figure 5A and B).
The staining frequency and intensity ofeach lectin to the signet
ring cells and enterocyte-like differentiated tumour cells of HT29
tumour cells in 5-FU-treated and saline-injected SCID mice at
days 24 and 26 are represented semiquantitatively in Table 2.
When the binding sites oftheN-acetylglucosamine-specific lectins
were compared, numerous binding sites for WGA were seen in the
cytoplasmic granules of signet ring cells in 5-FU-treated animals
when compared with controls. Binding of N-acetylgalactosamine
and galactose-speciflc lectins SBA (Figure 6), VVA (Figure 7)
and WFA (Figure 8) to the signet ring cells and enterocyte-like
differentiated tumour cells was considerably increased in animals
British JournalofCancer(1997) 00(0), 1011-1016
*
0 CancerResearch Campaign 19971014 R Sharma etal
5-
Control 5-FU Control 5-FU
Day 24 Day 26
Figure 3 Mean percentage ( s.e.m.) of mitotic and apoptotic tumour cells
and Ki-67-positive enterocytes in the HT29 tumours of 5-FU-treated SClD
mice and controls at days 24 and 26. Each value is based on ten areas from
a tumour. *Statistically different from controls, at P < 0.0001. U, Mitosis; [IDl,
epoptosis, M, Ki-67 enterocytes
n
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Figure 4 HT29 tumour of a saline-injected control immunostained with
Ki-67. It is evident that the nuclear antigen detected by Ki-67 is located on
enterocyte-like differentiated tumour cells (single arrows). One signet ring cell
is also labelled (double arrow). Bar = 50gm
B
Figure 5 A and B Mucin-containing cells of HT29 tumour from a control (A) and a SCID mouse injected with 5-FU (B) stained by PAS technique. Note the
differences in the distribution of signet ring cells in two groups. Bar = 12 ,um
Table 2 Lectin binding pattern in HT29 tumours of control and 5-FU treated SCID mice
Lectin Signet ring cells Enterocyte-like differentiated tumour cells
Day 24 Day 26 Day 24 Day 26
Control 5-FU Control 5-FU Control 5-FU Control 5-FU
WGA 1 ++ 2++ 1 + 3++ 2++ 2++ 1 + 2+
PWM 0 0 0 1+ 0 0 0 11+
SBA 20.. 40++ 20++ 30++ 20.. 30.. 2+ 30..
SJA O O O O O O O O
VVA 2... 3+++. 2+++. 3+++. 1 ++ 2++ 1 + 3...
WFA 2... 2++ 2+++ 4+++. 2++ 2++ 2+ 3...
SNA 0 0 0 0 0 0 0 0
UEA-1 0 0 0 0 0 0 0 0
PNA 1 ++ 3++ 2++ 4+++ 1 ++ 3+++ 1 + 3++
Numbers indicate staining frequency on a semiquantitatative scale ranging from 0 to 5 where 0 corresponds to no
reactive cells, 1 to occasional, 2 to a few, 3 to a moderate number and 4 to numerous reactive cells. Staining intensity,
(+++) strong; (++) moderate; (+) weak.
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Figure 6 Labelling of HT29 tumour with SBA in a SCID mouse treated with
5-FU and killed at day 26. Cells identified as signet ring cells and enterocyte-
like differentiated tumour cells are strongly labelled. Bar = 50 ,um
Figure 7 VVA-binding sites in a tumour of a 5-FU-treated SCID mouse at
day 26. Signet ring cells (S) and enterocyte-like differentiated tumour cells
(E) are heavily labelled. Bar = 50,m
treated with 5-FU. The other GalNAc-specific lectins (SJA and
SNA) and fucose-specific lectin (UEA-I) did not react with HT29
cells in either the 5-FU-treated or the saline-injected control
animals (see Table 2). There were considerable differences in the
binding ofPNA, agalactose-specific lectin. In HT29 tumours of5-
FU-treated mice, the signet ring cells and enterocyte-like differen-
tiated tumour cells showed increased binding of PNA (Figure 9)
compared with the controls.
DISCUSSION
The SCID mouse model of metastatic HT29 human colon cancer
established in our laboratory has recently been shown to be of
clinical relevance as the glycoconjugate expression indicative of
metastasis is the same in patients as it is in the human-derived
tumours grown in SCID mice (Schumacher et al, 1994 a,b) and
was used for the present study. The aim ofthe present study was to
investigate whether 5-FU chemotherapy in this clinically relevant
model system induces any change in cell number by modifying the
mitotic and/or apoptotic indices of tumour cells. As apoptosis is
lower than mitosis in a growing tumour, quantification of apo-
ptotic and mitotic indices in a 5-FU-treated human colonic adeno-
carcinoma xenograft system may elucidate the proliferation profile
ofthis disease. Ourresults show that, 24 h and 48 h after the end of
Figure 8 HT29 tumour from a 5-FU-treated SCID mouse stained with WFA.
A cluster of enterocyte-like differentiated tumour cells (arrow) and a signet
ring cell (S) are strongly labelled. Bar = 50 gim
1:1:: M :.e v.:::w.
Figure 9 PNA binding in a SCID mouse treated with 5-EU. The signet ring
cell (1) and enterocyte-like differentiated tumour cells (E) are labelled.
Bar = 50 gim
the drug treatment, the transplanted tumours showed a decreased
mitotic index in response to 5-FU, whereas the apoptotic index
was enhanced. In principle, chemotherapeutic treatment of tumour
cells can lead to an elongation of the time in which the tumour
cells are in mitosis (Camplejohn et al, 1980) and, in particular, 5-
EU can lead to a decrease in the mitotic index (Camplejohn et al,
1977). It has been reported that anti-cancer drugs induce apoptosis
in colorectal carcinoma cells (Makino et al, 1996), and measure-
ment ofapoptotic index may be important in cancerchemotherapy
(Williams, 1991; Wyllie, 1993).
Our data of tumour growth and apoptotic index indicate that the
5-FU-induced toxicity may be related in part to the enhanced
apoptosis in tumour cells. However, more detailed studies that
investigate the effect of 5-EU on the length at which apoptotic
figures can be observed have to be performed.
In this study, the therapeutic activity of 5-FU has been measured
using the tumourweight 24 h and 48 h after the end ofthe drug treat-
ment as acriterion oftumourgrowth inhibition. Treatment oftumour
xenografts with 5-EU for 4 days was found to reduce the tumour
weight significantly compared with the controls. Our data therefore
indicate that continuous infusion of 5-EU has significant in vivo
therapeutic efficacy against this HT29 human colon cancer model.
Further studies are needed to evaluate whether 5-EU treatment also
has any influence on metastases ofthis tumour to the lungs.
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The HT29 cell line is a multipotent cell population that differen-
tiates into the phenotype ofmature enterocytes (HT29-18-Cl) and
mucus-secreting goblet (HT29-18-N2) cells (Huet et al, 1987). In
our study, the quantitative assessment ofcell proliferation in HT29
tumours has shown that the nuclear antigen detected by Ki-67 is
expressed more in the enterocyte-like differentiated cells than in
the signet ring cells. Although the therapeutic failure could be due
to re-entry of signet ring cells into cell cycle, it would be inter-
esting to assess whether after cell division these cells differentiate
into mucin-containing goblet cells or enterocyte-like tumour cells.
The slow proliferation rate ofthe KI-67 positive goblet cells might
account for the failure ofchemotherapy thatinterferes with the cell
division mechanisms. It would therefore be of interest to evaluate
the number of signet ring cells in HT29 tumours of those SCID
mice treated by an apoptosis-inducing drug. These drugs should
therefore target both enterocyte-like and goblet cell-like tumour
cells equally. In this study, the increase in Ki-67 mean labelling
index 24 h after 5-FU treatment appears to be due to the prolonga-
tion ofcell cycle in enterocyte-like tumourcells (Camplejohn et al,
1977). The decrease of Ki-67 labelling index 48 h after the end of
5-FU treatment was consistent with the finding of lower mitotic
rate, lower tumour growth and increased apoptosis at this stage.
The PAS reaction showed appreciable differences in the goblet
cell-like differentiation ofsignet ring cells in HT29 tumourcells of
5-FU-treated animals and saline-injected controls. In the tumours
grown in SCID mice, the increase in the distribution of PAS-
positive cells after 5-FU treatment shows a shift towards the signet
ring cell phenotype compared with enterocyte stem cell pheno-
type. The possible reasons for the accumulation of signet ring
tumour cells could be a differentiating effect of 5-FU or a deple-
tion of the enterocyte stem cell phenotype by 5-FU. The latter
explanation seems more likely as only very few goblet-like cells
were Ki-67 positive, indicating that the majority of these cells
were non-replicating and thus less sensitive to 5-FU treatment.
The lectin-binding pattern also reflected an increase in the expres-
sion of particular glycoconjugates in response to 5-FU treatment.
The more marked binding of SBA, VVA, WFA and PNA, particu-
larly to the signet ring cells, would indicate that the 5-FU induces
an increase ofN-acetylgalactosamine and galactose residues to the
glycoconjugate core of intracellular mucins of HT29 cells.
Although the mechanisms by which anti-metabolites can affect
glycosylation are not completely understood (De Graff et al,
1993), our results suggest that a 5-FU-induced increase in differ-
entiation ofmucin-producing HT29 tumour cells could be respon-
sible for changes in their cellular glycoconjugates. However, other
factors, such as alterations in cell membrane sialoglycoconjugates
(Hindenburg et al, 1985) or the changes in activities of specific
glycosyltransferases (Paulson and Colley, 1989), might be addi-
tional mechanisms of 5-FU in influencing cellular glycoconjugate
composition.
In summary, our study demonstrates that anti-tumour activity
of 5-FU is not confined to its effects on cell proliferation and
apoptosis but is also apparent in glycoconjugate expression of
HT29 cells implanted in SCID mice. However, the correlation
between the 5-FU-induced changes in mitotic and apoptotic
indices on the one hand and changes in glycosylation on the other,
particularly at the level of the intermediate carbohydrate metabo-
lism, remain to be resolved. Our data on effects of 5-FU on local
tumour development may serve as a basis for further studies
aimed at the identification of regulatory factors involved in the
metastatic spread of tumour cells in SCID mice. This might lead
to new chemotherapeutic concepts for influencing local tumour
growth and metastasis ofhuman colonic carcinoma.
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